Sugi Predict

Sugi Predict / Targets / CAMK2A

CAMK2A

Calcium/calmodulin-dependent protein kinase type II subunit alpha · Q9UQM7 · CAMK2A on Sugi Atlas →

36,400 patent compounds predicted against CAMK2A, 25,558 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL71912 SCHEMBL71912 0.51 5/20
Diclofenac Diclofenac (SCHEMBL2799) 0.76 3/20
Diclofenac Diclofenac (SCHEMBL24010) 0.74 3/20
Diclofenac Diclofenac (SCHEMBL40785) 0.74 3/20
SCHEMBL98881 SCHEMBL98881 0.57 3/20
Aceclofenac Aceclofenac (SCHEMBL25734) 0.56 3/20
Diclofenac Diclofenac (SCHEMBL24009) 0.56 3/20
Diclofenac Diclofenac (SCHEMBL40784) 0.56 3/20
SCHEMBL100736 SCHEMBL100736 0.50 3/20
SCHEMBL100040 SCHEMBL100040 0.48 3/20
SCHEMBL100903 SCHEMBL100903 0.47 3/20
SCHEMBL101889 SCHEMBL101889 0.46 3/20
SCHEMBL101518 SCHEMBL101518 0.45 3/20
SCHEMBL99210 SCHEMBL99210 0.43 3/20
SCHEMBL101240 SCHEMBL101240 0.41 3/20
Ruxolitinib Ruxolitinib (SCHEMBL99225) 1.00 2/20
Ruxolitinib Ruxolitinib (SCHEMBL101279) 1.00 2/20
SCHEMBL99245 SCHEMBL99245 0.98 2/20
SCHEMBL99371 SCHEMBL99371 0.98 2/20
SCHEMBL103135 SCHEMBL103135 0.98 2/20

Clinical trials — most relevant to CAMK2A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
COMS for Chronic Ulcers Treatment PHASE4RECRUITING
The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia PHASE4COMPLETED
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion PHASE4RECRUITING
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
A Trial of Levodopa in Angelman Syndrome PHASE2/PHASE3COMPLETED
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women? PHASE2COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
Calcium Channel Blockade in Primary Aldosteronism PHASE2COMPLETED
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients PHASE1COMPLETED
Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome PHASE1COMPLETED
Physiologic Effects of Topiramate on Cognition PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
D-aspartate and Therapeutic Exercise EARLY_PHASE1UNKNOWN
Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE) EARLY_PHASE1RECRUITING
Epithelioid Haemangioendothelioma Observational Study nanRECRUITING
Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia nanRECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Human Epilepsy Genetics--Neuronal Migration Disorders Study nanRECRUITING
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13) nanNOT_YET_RECRUITING
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life nanCOMPLETED
Biomarkers of CASH nanACTIVE_NOT_RECRUITING
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms nanCOMPLETED
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease nanUNKNOWN
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury nanCOMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CAMK2A binder may also engage these)

ProteinNameSimilarity
P11275 — 1.000 P11275 →
Q5RCC4 — 1.000 Q5RCC4 →
CAMK2D Calcium/calmodulin-dependent protein kinase type II subunit delta 1.000 landscape →
Q2HJF7 — 1.000 Q2HJF7 →
P11798 — 1.000 P11798 →
Q95266 — 1.000 Q95266 →
Q6DEH3 — 1.000 Q6DEH3 →
Q6PHZ2 — 1.000 Q6PHZ2 →
P11730 — 1.000 P11730 →
Q5ZKI0 — 1.000 Q5ZKI0 →
Q9DG02 — 1.000 Q9DG02 →
P08413 — 0.998 P08413 →
O77708 — 0.996 O77708 →
P15791 — 0.995 P15791 →
CAMK2G Calcium/calmodulin-dependent protein kinase type II subunit gamma 0.995 landscape →
A8WXF6 — 0.994 A8WXF6 →
Q923T9 — 0.994 Q923T9 →
Q6DGS3 — 0.993 Q6DGS3 →
Q00168 — 0.993 Q00168 →
Q3MHJ9 — 0.991 Q3MHJ9 →
P28652 — 0.991 P28652 →
Q8RWL2 — 0.991 Q8RWL2 →
Q9M101 — 0.991 Q9M101 →
Q869W6 — 0.990 Q869W6 →
Q2QX45 — 0.990 Q2QX45 →
Q6PFQ0 — 0.990 Q6PFQ0 →
Q63531 — 0.989 Q63531 →
Q9FMP5 — 0.989 Q9FMP5 →
Q8VDF3 — 0.989 Q8VDF3 →
P10665 — 0.989 P10665 →